Key Facts

Invested since 2012
Based in Thuringia

About the company

oncgnostics develops – based on proprietary epigenetic biomarkers – highly reliable molecular in-vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in oncology.

Do you want to

know more about this company?

Zum Artikel

Dr. Bernd Goergen Partner

Dr. Bernd GoergenPartner

oncgnostics in the news

Zum Artikel

News

5. September 2023

Hong Kong firm invests in Jena-based Oncgnostics GmbH

Zum Artikel

Story

13. September 2022

Our mission? To help more people!

Zum Artikel

Press

29. January 2015

Molecular diagnostics company oncgnostics GmbH closes Series A financing round for CE mark and market entry of its cervical cancer diagnostics test GynTect®

Zum Artikel

Press

16. April 2012

High-Tech Gründerfonds and STIFT invest into molecular cancer diagnostics from Jena

More startups from Life Sciences